 GSK PLC LSE:GSK, NYSE:GSK is growing at a robust rate and showing increasing confidence in its HIV treatments, according to Jefferies analysts, though they cut their share price target due to long-term challenges and cost worries. Jefferies kept its hold rating and suggested a 2022 price target of 1,575p, a 4 drop on original targets, but this still sits above its current price of 1,415p. 